Search 

Adjuvant Therapeutics Inc. is a clinical stage medical device company that is developing a system to improve the effectiveness of radiotherapy for cancer treatment. The system, called OncO2™, uses innovative technology to increase oxygen concentrations in tumours, making them more sensitive to radiation.

Poor tumour oxygen has long been known to make radiation less effective, particularly in cancers of the head and neck, where 5 year survival rates range from 17% to about 63%. The OncO2™ system allows for individual optimization of therapy to maximize the effectiveness of the radiation.

Adjuvant Therapeutics will initially focus on head and neck cancers, however the OncO2™ system can also address other types of resistant cancers such as those of the cervix and bladder.

The Advanced Medical Technology Association (AdvaMed), is a trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world. AdvaMed represents 80 percent of medical technology firms in the United States and acts as the common voice for companies producing medical devices, diagnostic products and health information systems. AdvaMed members produce nearly 90 percent of the health care technology purchased annually in the United States and more than 40 percent purchased annually around the world. AdvaMed's member companies range from the largest to the smallest medical technology innovators and companies.

AdvaMed 2015 - October 5-7, San Diego - is the leading MedTech Conference in North America, bringing more than 1,000 companies together in a uniquely multifaceted environment for business development, capital formation, innovative technology showcasing, world-class educational opportunities and networking. An event rich in international flavor and featuring a deep, diverse attendee list that includes influential policy-makers, business executives and media, AdvaMed 2015 seeks to advance industry discussion from key perspectives through detailed panel sessions, executive forums and more. It is a “must-attend” event for any MedTech company.

Advent Life Sciences

We invest predominantly in early and mid-stage life sciences companies.  We seek to back truly innovative companies that have a first-in-class or best-in-class approach and who are looking for a well-connected partner on the road to success.

Our investments cover a range of sectors within life sciences, including new drug discovery, enabling technologies, med tech and diagnostics.Advent Life Sciences is one of Europe’s leading venture teams investing in life sciences businesses. We are a deliberately small, and highly focused team of senior individuals, with long-standing track records of entrepreneurial and investment success across the UK, Europe and the USA.

Real people. Real insight. Real value.

Innovation. Clarity. Execution.

ALIAD is the venture capital subsidiary of the Air Liquide Group (L'Air Liquide S.A.), one of the largest multinational providers of industrial and medical gases and related activities, headquartered in Paris, France. The healthcare division of the Air Liquide Group has been playing a significant role in healthcare with over €2 billion in revenue. 
ALIAD aims to promote the Group’s growth and access to innovations through taking minority stakes in innovative technology start-ups outside the Group. ALIAD can lead or co-invest with other investors. Typical allocations are made in equity and range from €1-10 million. ALIAD is currently seeking new opportunities across a wide geography, including Western Europe, North and South America and Asia.

Apple Tree Partners is a private equity fund that was established in 1999 and based in New York, NY, with satellite offices in Princeton, NJ, Cambridge, MA and Brussels, Belgium. The firm controls up to $1.75 billion in assets under management and makes equity investments ranging from $100,000 for academic spinouts to $150 million dollar in later stage deals. The firm seeks to make investments around the globe with a focus on creating and building companies located within the US and Europe.

Did you know that 10-15% of LASIK patients are turned away due to inadequate eye measurement equipment?  This laser refractive eye surgery market has a crying need for the next generation measurement tool now to capture these additional patients and improve on existing procedures and outcomes.

Did you know that ophthalmologists suffer significant measurement problems in accurately predicting the ELP (Effective Lens Position) in cataract surgery/Intra-Ocular Lens (IOL) procedures?

The ArcScan Artemis-3 system addresses both of these market needs and more.

ArcScan has already raised all funding needed ($3 million) to enter the laser refractive surgery market, with product introduction expected in 12 months.

The ArcScan Series A Preferred funding round of $3 million currently has $1 million available to investors from now through February, 2015, or until sold-out, whichever occurs first.

ArcScan is attending the RESI conference to raise the final $1,000,000 in Series A Preferred share subscriptions, which will allow us to accelerate entry into the large cataract surgery/IOL market and nearly double the size of the business.

Please request a meeting at RESI or contact ArcScan CEO Andy Levien for an executive summary and further investment details.

Arcus Ventures was founded in 2007 and is based in New York City. Arcus Ventures is currently investing from its second fund, which had a first close of $36m in 2014 and is targeting a raise of $100m. The firm typically invests $2-5 million. Arcus invests primarily in the USA but is also open to considering opportunities in Canada.